FI19991925A - Pharmaceutical solutions of levosimendan - Google Patents

Pharmaceutical solutions of levosimendan

Info

Publication number
FI19991925A
FI19991925A FI991925A FI19991925A FI19991925A FI 19991925 A FI19991925 A FI 19991925A FI 991925 A FI991925 A FI 991925A FI 19991925 A FI19991925 A FI 19991925A FI 19991925 A FI19991925 A FI 19991925A
Authority
FI
Finland
Prior art keywords
levosimendan
pharmaceutical solutions
pharmaceutical
solutions
Prior art date
Application number
FI991925A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI109659B (en
Inventor
Reijo Baeckstroem
Paeivi Granvik
Ritva Haikala
Sirpa Pelttari
Eva Saukko
Reija Yrjoelae
Original Assignee
Orion Yhtymae Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8555263&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI19991925(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Yhtymae Oyj filed Critical Orion Yhtymae Oyj
Priority to FI991925A priority Critical patent/FI109659B/en
Priority to UA2002042873A priority patent/UA73954C2/en
Priority to MYPI20003682A priority patent/MY125984A/en
Priority to ARP000104525A priority patent/AR025449A1/en
Priority to TW089117581A priority patent/TWI242434B/en
Priority to CO00067212A priority patent/CO5180582A1/en
Priority to HU0202749A priority patent/HU228340B1/en
Priority to EA200200348A priority patent/EA005067B1/en
Priority to PT00958562T priority patent/PT1210085E/en
Priority to BRPI0013924A priority patent/BRPI0013924B8/en
Priority to JP2001522969A priority patent/JP4708648B2/en
Priority to KR20027002923A priority patent/KR100869752B1/en
Priority to SK327-2002A priority patent/SK287154B6/en
Priority to AU70044/00A priority patent/AU771027B2/en
Priority to DE60025627T priority patent/DE60025627T2/en
Priority to MXPA02002423A priority patent/MXPA02002423A/en
Priority to IL14837900A priority patent/IL148379A0/en
Priority to TR2002/00620T priority patent/TR200200620T2/en
Priority to US10/070,689 priority patent/US6730673B1/en
Priority to YUP-169/02A priority patent/RS50445B/en
Priority to CZ20020788A priority patent/CZ303095B6/en
Priority to ES00958562T priority patent/ES2256034T3/en
Priority to EP00958562A priority patent/EP1210085B1/en
Priority to PCT/FI2000/000761 priority patent/WO2001019334A2/en
Priority to SI200030801T priority patent/SI1210085T1/en
Priority to CNB008126453A priority patent/CN1203855C/en
Priority to CA002382013A priority patent/CA2382013C/en
Priority to PL354028A priority patent/PL202356B1/en
Priority to MEP-2008-866A priority patent/ME00523B/en
Priority to AT00958562T priority patent/ATE315937T1/en
Priority to NZ517605A priority patent/NZ517605A/en
Priority to DK00958562T priority patent/DK1210085T3/en
Priority to EEP200200129A priority patent/EE05375B1/en
Publication of FI19991925A publication Critical patent/FI19991925A/en
Priority to IL148379A priority patent/IL148379A/en
Priority to NO20021090A priority patent/NO331989B1/en
Priority to ZA200201828A priority patent/ZA200201828B/en
Priority to IS6296A priority patent/IS2244B/en
Priority to BG106589A priority patent/BG65827B1/en
Priority to HR20020298A priority patent/HRP20020298B1/en
Publication of FI109659B publication Critical patent/FI109659B/en
Application granted granted Critical
Priority to HK03101189.6A priority patent/HK1049282B/en
Priority to US10/703,565 priority patent/US6943164B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FI991925A 1999-09-10 1999-09-10 Pharmaceutical solutions of levosimendan FI109659B (en)

Priority Applications (41)

Application Number Priority Date Filing Date Title
FI991925A FI109659B (en) 1999-09-10 1999-09-10 Pharmaceutical solutions of levosimendan
UA2002042873A UA73954C2 (en) 1999-09-10 2000-08-09 Levosimendan-containing solution for pharmaceutical use, particularly for intravenous administration
MYPI20003682A MY125984A (en) 1999-09-10 2000-08-11 Pharmaceutical solutions of levosimendan.
ARP000104525A AR025449A1 (en) 1999-09-10 2000-08-30 PHARMACEUTICAL SOLUTIONS OF LEVOSIMENDAN
TW089117581A TWI242434B (en) 1999-09-10 2000-08-30 Pharmaceutical solutions of levosimendan
CO00067212A CO5180582A1 (en) 1999-09-10 2000-09-06 PHARMACEUTICAL SOLUTIONS OF LEVOSIMENDAN
CZ20020788A CZ303095B6 (en) 1999-09-10 2000-09-08 Aqueous intravenous infusion solution or pharmaceutical solution comprising levosimendan
CNB008126453A CN1203855C (en) 1999-09-10 2000-09-08 Pharmaceutical solutions for levosimendan
PT00958562T PT1210085E (en) 1999-09-10 2000-09-08 LEVOSIMENDANO PHARMACEUTICAL SOLUTIONS
BRPI0013924A BRPI0013924B8 (en) 1999-09-10 2000-09-08 pharmaceutical solutions of levosimendan
JP2001522969A JP4708648B2 (en) 1999-09-10 2000-09-08 Pharmaceutical solution of levosimendan
KR20027002923A KR100869752B1 (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan
SK327-2002A SK287154B6 (en) 1999-09-10 2000-09-08 Aqueous intravenous infusion solution or pharmaceutical solution comprising levosimendan
AU70044/00A AU771027B2 (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan
DE60025627T DE60025627T2 (en) 1999-09-10 2000-09-08 PHARMACEUTICAL SOLUTION OF LEVOSIMENDAN
MXPA02002423A MXPA02002423A (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan.
IL14837900A IL148379A0 (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan
TR2002/00620T TR200200620T2 (en) 1999-09-10 2000-09-08 Levosimendan pharmaceutical solutions
US10/070,689 US6730673B1 (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan
YUP-169/02A RS50445B (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan
HU0202749A HU228340B1 (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan
ES00958562T ES2256034T3 (en) 1999-09-10 2000-09-08 PHARMACEUTICAL SOLUTIONS OF LEVOSIMENDANO.
EP00958562A EP1210085B1 (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan
PCT/FI2000/000761 WO2001019334A2 (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan
SI200030801T SI1210085T1 (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan
EA200200348A EA005067B1 (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan
CA002382013A CA2382013C (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan
PL354028A PL202356B1 (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan
MEP-2008-866A ME00523B (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan
AT00958562T ATE315937T1 (en) 1999-09-10 2000-09-08 PHARMACEUTICAL SOLUTION OF LEVOSIMENDAN
NZ517605A NZ517605A (en) 1999-09-10 2000-09-08 Levosimendan solutions at a pH less than 5 particularly for intravenous administration
DK00958562T DK1210085T3 (en) 1999-09-10 2000-09-08 Pharmaceutical solutions of levosimendan
EEP200200129A EE05375B1 (en) 1999-09-10 2000-09-08 Levosimendan Pharmaceutical Formulations
IL148379A IL148379A (en) 1999-09-10 2002-02-26 Pharmaceutical solutions of levosimendan
NO20021090A NO331989B1 (en) 1999-09-10 2002-03-05 Aqueous intravenous infusion solution and intravenous infusion concentrate comprising levosimendan.
ZA200201828A ZA200201828B (en) 1999-09-10 2002-03-05 Pharmaceutical solutions of levosimendan.
IS6296A IS2244B (en) 1999-09-10 2002-03-06 Levosimendan drug solutions
BG106589A BG65827B1 (en) 1999-09-10 2002-04-05 Pharmaceutical solutions of levosimendan
HR20020298A HRP20020298B1 (en) 1999-09-10 2002-04-08 Pharmaceutical solutions of levosimendan
HK03101189.6A HK1049282B (en) 1999-09-10 2003-02-18 Pharmaceutical solutions of levosimendan
US10/703,565 US6943164B2 (en) 1999-09-10 2003-11-10 Pharmaceutical solutions of levosimendan

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI991925A FI109659B (en) 1999-09-10 1999-09-10 Pharmaceutical solutions of levosimendan
FI991925 1999-09-10

Publications (2)

Publication Number Publication Date
FI19991925A true FI19991925A (en) 2001-03-10
FI109659B FI109659B (en) 2002-09-30

Family

ID=8555263

Family Applications (1)

Application Number Title Priority Date Filing Date
FI991925A FI109659B (en) 1999-09-10 1999-09-10 Pharmaceutical solutions of levosimendan

Country Status (39)

Country Link
US (2) US6730673B1 (en)
EP (1) EP1210085B1 (en)
JP (1) JP4708648B2 (en)
KR (1) KR100869752B1 (en)
CN (1) CN1203855C (en)
AR (1) AR025449A1 (en)
AT (1) ATE315937T1 (en)
AU (1) AU771027B2 (en)
BG (1) BG65827B1 (en)
BR (1) BRPI0013924B8 (en)
CA (1) CA2382013C (en)
CO (1) CO5180582A1 (en)
CZ (1) CZ303095B6 (en)
DE (1) DE60025627T2 (en)
DK (1) DK1210085T3 (en)
EA (1) EA005067B1 (en)
EE (1) EE05375B1 (en)
ES (1) ES2256034T3 (en)
FI (1) FI109659B (en)
HK (1) HK1049282B (en)
HR (1) HRP20020298B1 (en)
HU (1) HU228340B1 (en)
IL (2) IL148379A0 (en)
IS (1) IS2244B (en)
ME (1) ME00523B (en)
MX (1) MXPA02002423A (en)
MY (1) MY125984A (en)
NO (1) NO331989B1 (en)
NZ (1) NZ517605A (en)
PL (1) PL202356B1 (en)
PT (1) PT1210085E (en)
RS (1) RS50445B (en)
SI (1) SI1210085T1 (en)
SK (1) SK287154B6 (en)
TR (1) TR200200620T2 (en)
TW (1) TWI242434B (en)
UA (1) UA73954C2 (en)
WO (1) WO2001019334A2 (en)
ZA (1) ZA200201828B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109659B (en) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Pharmaceutical solutions of levosimendan
FI20010233A0 (en) * 2001-02-08 2001-02-08 Orion Corp A method for treating heart failure
CN100428937C (en) * 2003-10-30 2008-10-29 北京海合天科技开发有限公司 Levosimendan freeze-drying composition
CN100367964C (en) * 2004-04-29 2008-02-13 王思清 Inclusion preparation of levosimendan and beta cyclodextrin
JP2008530186A (en) * 2005-02-18 2008-08-07 オリオン コーポレーション Heart failure treatment
JP2010514778A (en) * 2006-12-28 2010-05-06 オリオン コーポレーション Levosimendan formulation for parenteral administration
WO2012093404A2 (en) 2011-01-03 2012-07-12 Gufic Biosciences Limited Parenteral formulations of levosimendan
US8697118B2 (en) * 2011-10-18 2014-04-15 St. Teresa Medical, Inc. Stabilizers for hemostatic products
BR112014028602B1 (en) * 2012-05-18 2023-10-24 Luoda Pharma Limited ORALLY BIOAVAILABLE NON-AQUEOUS LIQUID FORMULATION FOR ORAL ADMINISTRATION
CN105106113B (en) * 2015-09-30 2019-07-26 济南康和医药科技有限公司 A kind of Levosimendan Injections and preparation method thereof
CA3004362C (en) * 2015-11-06 2022-10-04 Carinopharm Gmbh Improved formulations of levosimendan for intravenous administration as infusion or injection and of infusion concentrate
WO2017083050A1 (en) 2015-11-12 2017-05-18 St. Teresa Medical, Inc. A method of sealing a durotomy
CN108261398A (en) * 2016-12-30 2018-07-10 齐鲁制药有限公司 A kind of injection pharmaceutical preparation containing Levosimendan and preparation method thereof
US10953128B2 (en) 2017-11-02 2021-03-23 St. Teresa Medical, Inc. Fibrin sealant products
CN111474289A (en) * 2019-10-31 2020-07-31 武汉嘉诺康医药技术有限公司 Method for separating and analyzing levosimendan and levosimendan by using reverse phase chromatography
JP2023507626A (en) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド Levosimendan for the treatment of pulmonary hypertension with preserved ejection fraction heart failure (PH-HF-pEF)
CN111514147B (en) * 2020-05-12 2021-09-17 成都欣捷高新技术开发股份有限公司 Levosimendan sodium medicinal composition for acute decompensated heart failure symptoms and preparation method thereof
US11760730B2 (en) * 2021-01-11 2023-09-19 Navinta, Llc Process for the preparation of high purity Levosimendan
WO2023027670A2 (en) * 2021-08-23 2023-03-02 Tum Ekip Ilac Anonim Sirketi Lyophilized levosimendan compositions
CN115518037A (en) * 2022-10-14 2022-12-27 上药东英（江苏）药业有限公司 Safe and stable-quality levosimendan injection composition and preparation method thereof
CN116473930B (en) * 2023-05-17 2023-12-15 山东泰合医药科技有限公司 Levosimendan for injection and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
GB9606474D0 (en) 1996-03-27 1996-06-05 Orion Yhytmo Oy Method for obtaining pure enantiomers of a pyridazinone derivative
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI980902A (en) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Stable compositions of levosimendan
FI109659B (en) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Pharmaceutical solutions of levosimendan

Also Published As

Publication number Publication date
IL148379A (en) 2006-12-10
SK287154B6 (en) 2010-01-07
WO2001019334A3 (en) 2001-11-15
HRP20020298A2 (en) 2003-06-30
DE60025627D1 (en) 2006-04-06
YU16902A (en) 2004-09-03
NZ517605A (en) 2003-08-29
ME00523B (en) 2011-10-10
NO20021090L (en) 2002-03-05
HK1049282B (en) 2005-12-30
SK3272002A3 (en) 2002-12-03
HRP20020298B1 (en) 2007-02-28
US6730673B1 (en) 2004-05-04
US6943164B2 (en) 2005-09-13
KR100869752B1 (en) 2008-11-21
NO331989B1 (en) 2012-05-21
EE200200129A (en) 2003-04-15
KR20020048400A (en) 2002-06-22
DE60025627T2 (en) 2006-11-16
EP1210085A2 (en) 2002-06-05
PL354028A1 (en) 2003-12-15
CN1373665A (en) 2002-10-09
HUP0202749A2 (en) 2003-02-28
MY125984A (en) 2006-09-29
IS2244B (en) 2007-05-15
EP1210085B1 (en) 2006-01-18
JP2003509351A (en) 2003-03-11
FI109659B (en) 2002-09-30
BR0013924B1 (en) 2013-09-24
ATE315937T1 (en) 2006-02-15
AR025449A1 (en) 2002-11-27
PT1210085E (en) 2006-05-31
HUP0202749A3 (en) 2003-03-28
HU228340B1 (en) 2013-03-28
DK1210085T3 (en) 2006-05-08
NO20021090D0 (en) 2002-03-05
BG65827B1 (en) 2010-02-26
AU771027B2 (en) 2004-03-11
CA2382013C (en) 2009-08-11
US20040106617A1 (en) 2004-06-03
AU7004400A (en) 2001-04-17
IL148379A0 (en) 2002-09-12
EA200200348A1 (en) 2002-08-29
CZ2002788A3 (en) 2002-11-13
RS50445B (en) 2010-03-02
UA73954C2 (en) 2005-10-17
HK1049282A1 (en) 2003-05-09
WO2001019334A2 (en) 2001-03-22
TR200200620T2 (en) 2002-09-23
BR0013924A (en) 2002-05-21
TWI242434B (en) 2005-11-01
ES2256034T3 (en) 2006-07-16
EA005067B1 (en) 2004-10-28
SI1210085T1 (en) 2006-04-30
ZA200201828B (en) 2003-08-27
CO5180582A1 (en) 2002-07-30
BG106589A (en) 2002-11-29
IS6296A (en) 2002-03-06
MXPA02002423A (en) 2002-08-12
EE05375B1 (en) 2011-02-15
CA2382013A1 (en) 2001-03-22
PL202356B1 (en) 2009-06-30
CN1203855C (en) 2005-06-01
JP4708648B2 (en) 2011-06-22
BRPI0013924B8 (en) 2021-05-25
CZ303095B6 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
FI19991925A (en) Pharmaceutical solutions of levosimendan
ATE392890T1 (en) HYDROGEL-CONTROLLED DOSAGE FORM
DE60029883D1 (en) Medical nebulizer
NO20021400D0 (en) Therapeutic conazoline derivatives
DK1637127T3 (en) THERAPEUTIC MICROSUM
ATE485823T1 (en) COMBINATION PREPARATIONS CONTAINING (E)-7-Ä4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-
DK1466615T3 (en) Pharmaceutical preparation
PT1237857E (en) NEW FENALQUILOXY-PHENYL DERIVATIVES
NO20022606D0 (en) Pharmaceutical combinations
DK1275397T3 (en) Local drug
NO20014926D0 (en) Pharmaceutical compounds
DE69941129D1 (en) Senior Citizen
ID30397A (en) PRUKALOPRIDA ORAL SOLUTION
DE60029273D1 (en) Titanium Tinoxidfilme
EE200100697A (en) Pharmaceutical complex
ID30381A (en) USE OF ARILALKANOILPIRIDAZINA
NO20001235D0 (en) Wheelchair
PT1232141E (en) ETERIES OF O-DESMETIL-VENLAFAXIN
DE50009295D1 (en) NETWORK-FREE PREPARATIONS
UA2855S (en) PHARMACEUTICAL TABLET
SE9903207D0 (en) Medical system
SE9901114D0 (en) Reduction of Nox

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: ORION CORPORATION

Free format text: ORION CORPORATION